COMPASS Study for Metastatic Castration-resistant Prostate Cancer
COMPASS: Correlative COMPAnion Study to Predict SYNERGY-201 Clinical Trial Responders
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Monika Anand, PhD
- Phone Number: 919-681-8838
- Email: monika.anand@duke.edu
Study Contact Backup
- Name: Kellie Shobe, MS, BSN, RN
- Phone Number: 919-684-8299
- Email: kellie.shobe@duke.edu
Study Locations
-
-
California
-
San Francisco, California, United States, 94158
- Recruiting
- UCSF Helen Diller Family Comprehensive Cancer Center
-
Contact:
- Rahul Aggarwal, MD
- Phone Number: (415) 476-4616
- Email: rahul.aggarwal@ucsf.edu
-
Contact:
- Kelly Fitzgerald, MD
- Phone Number: (415) 476-4616
- Email: Kelly.Fitzgerald@ucsf.edu
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109-2800
- Recruiting
- Rogel Cancer Center
-
Contact:
- Zachery Reichert, MD
- Phone Number: 800-865-1125
- Email: zreiche@med.umich.edu
-
Contact:
- Zachery Reichert, MD
- Phone Number: 800-865-1125
- Email: CancerAnswerLine@med.umich.edu
-
-
North Carolina
-
Durham, North Carolina, United States, 27705
- Recruiting
- Duke University
-
Contact:
- Kellie Shobe, MS, BSN, RN
- Phone Number: 919-684-8299
- Email: kellie.shobe@duke.edu
-
Contact:
- Monika Monika Anand, PhD
- Phone Number: 919-681-8838
- Email: monika.anand@duke.edu
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792
- Recruiting
- University of Wisconsin Carbone Cancer Center
-
Contact:
- Glenn Liu, MD
- Phone Number: 800-622-8922
- Email: gxl@medicine.wisc.edu
-
Contact:
- UW Clinical Trial Navigation Team Cancer Connect
- Phone Number: 800-622-8922
- Email: cancerconnect@uwcarbone.wisc.edu
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Willing and able to provide written informed consent for this study and HIPAA authorization for the release of personal health information.
- Age >18
- Participating in the SYNGERY-201 clinical trial.
Exclusion Criteria:
- History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study
- History or current evidence of any condition, therapy, or laboratory abnormality that might interfere with the subject's participation for the full duration of the study
- History or current evidence of any condition, therapy, or laboratory abnormality that is not in the best interest of the subject to participate (in the opinion of the treating investigator)
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Men who are participating in the SYNERGY-201 clinical trial (NCT06228053).
Men with metastatic castration resistant prostate cancer (mCRPC) who are participating in the SYNERGY-201 clinical trial (NCT06228053) and who also agree to participate in this study will have blood collected for circulating tumor DNA (ctDNA) and immune cell profiling assessments and other research assessments at baseline, Cycle 3 Day 1 of SYNERGY-201 and at the time of the decision to discontinue the SYNERGY-201 study drug.
A subset of up to 20 participants will also undergo tumor biopsies at the baseline and Cycle 3 Day 1 visits of SYNERGY-201.
|
CXCR2 biomarker expression will be measured in tumor and immune cell samples
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of participants with Tumor CXCR2 biomarker expression associated with clinical benefit (CB)
Time Frame: 6 months from Cycle 1 Day 1 (each cycle is 21 days)
|
The association between tumor CXCR2 (dichotomized as absent or present CXCR2 levels in tumor at baseline as compared to negative control tissue) and CB will be measured using an odds ratio with 95% CI.
|
6 months from Cycle 1 Day 1 (each cycle is 21 days)
|
|
Number of participants with Immune cell CXCR2 biomarker expression associated with clinical benefit (CB)
Time Frame: 6 months from Cycle 1 Day 1 (each cycle is 21 days)
|
The association between immune cell CXCR2 (dichotomized as present or absent in any myeloid immune cell subset) and CB will be measured using an odds ratio with 95% CI.
|
6 months from Cycle 1 Day 1 (each cycle is 21 days)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of participants with both tumor CXCR2 expression and circulating tumor DNA androgen receptor (AR) genetic alterations - TP53
Time Frame: Baseline
|
The CXCR2 expression in tumor will be dichotomized as present or absent.
Each ctDNA genetic alteration (such as TP53 AR genetic alteration) will be categorized as present or absent.
|
Baseline
|
|
Number of participants with both tumor CXCR2 expression and circulating tumor DNA androgen receptor (AR) genetic alterations - RB1
Time Frame: Baseline
|
The CXCR2 expression in tumor will be dichotomized as present or absent.
Each ctDNA genetic alteration (such as RB1 AR genetic alteration) will be categorized as present or absent.
|
Baseline
|
|
Number of participants with both tumor CXCR2 expression and circulating tumor DNA androgen receptor (AR) genetic alterations - PTEN
Time Frame: Baseline
|
The CXCR2 expression in tumor will be dichotomized as present or absent.
Each ctDNA genetic alteration (such as PTEN AR genetic alteration) will be categorized as present or absent.
|
Baseline
|
|
Number of participants with both tumor CXCR2 expression and NEPC phenotype on biopsy
Time Frame: Baseline
|
CXCR2 expression in tumor will be dichotomized as present or absent and NEPC phenotype will be based on the biopsy and categorized as yes or no.
|
Baseline
|
|
Number of participants with both immune cell CXCR2 expression and circulating tumor DNA androgen receptor (AR) genetic alterations - TP53
Time Frame: Baseline
|
The CXCR2 expression in immune cells will be dichotomized as present or absent.
Each ctDNA genetic alteration (such as TP53 AR genetic alteration) will be categorized as present or absent.
|
Baseline
|
|
Number of participants with both immune cell CXCR2 expression and circulating tumor DNA androgen receptor (AR) genetic alterations - RB1
Time Frame: Baseline
|
The CXCR2 expression in immune cells will be dichotomized as present or absent.
Each ctDNA genetic alteration (such as RB1 AR genetic alteration) will be categorized as present or absent.
|
Baseline
|
|
Number of participants with both immune cell CXCR2 expression and circulating tumor DNA androgen receptor (AR) genetic alterations - PTEN
Time Frame: Baseline
|
The CXCR2 expression in immune cells will be dichotomized as present or absent.
Each ctDNA genetic alteration (such as PTEN AR genetic alteration) will be categorized as present or absent.
|
Baseline
|
|
Number of participants with both immune cell CXCR2 expression and NEPC phenotype on biopsy
Time Frame: Baseline
|
CXCR2 expression in immune cells will be dichotomized as present or absent and NEPC phenotype will be based on the biopsy and categorized as yes or no.
|
Baseline
|
|
Median progression-free survival (PFS) for participants with tumor CXCR2 expression
Time Frame: Up to 3 years after Cycle 1 Day 1 (each cycle is 21 days)
|
Median PFS and 95% CI estimated by the Kaplan-Meier approach will be reported by tumor CXCR2 expression (present or absent).
|
Up to 3 years after Cycle 1 Day 1 (each cycle is 21 days)
|
|
Median Progression-Free Survival (PFS) for participants with immune cells CXCR2 expression
Time Frame: Up to 3 years after Cycle 1 Day 1 (each cycle is 21 days)
|
Median PFS and 95% CI estimated by the Kaplan-Meier approach will be reported by immune cell CXCR2 expression (present or absent).
|
Up to 3 years after Cycle 1 Day 1 (each cycle is 21 days)
|
|
Median overall survival (OS) for participants with tumor CXCR2 expression
Time Frame: Up to 3 years after Cycle 1 Day 1 (each cycle is 21 days)
|
Median OS and 95% CI estimated by the Kaplan-Meier approach will be reported by tumor CXCR2 expression (present or absent).
|
Up to 3 years after Cycle 1 Day 1 (each cycle is 21 days)
|
|
Median overall survival (OS) for participants with immune cells CXCR2 expression
Time Frame: Up to 3 years after Cycle 1 Day 1 (each cycle is 21 days)
|
Median OS and 95% CI estimated by the Kaplan-Meier approach will be reported by immune cell CXCR2 expression (present or absent).
|
Up to 3 years after Cycle 1 Day 1 (each cycle is 21 days)
|
|
Proportion of participants with CXCR2 expression in tumor over time
Time Frame: Cycle 1 Day 1 (each cycle is 21 days), Cycle 3 Day 1 (each cycle is 21 days), and progression (up to 3 years)
|
The proportion of patients with CXCR2 expression in tumor (present or absent) will be reported at C1D1, C3D1, and progression.
|
Cycle 1 Day 1 (each cycle is 21 days), Cycle 3 Day 1 (each cycle is 21 days), and progression (up to 3 years)
|
|
Proportion of participants with CXCR2 expression in immune cells over time
Time Frame: Cycle 1 Day 1 (each cycle is 21 days), Cycle 3 Day 1 (each cycle is 21 days), and progression (up to 3 years)
|
The proportion of patients with CXCR2 expression in immune cells (present or absent) will be reported at C1D1, C3D1, and progression.
|
Cycle 1 Day 1 (each cycle is 21 days), Cycle 3 Day 1 (each cycle is 21 days), and progression (up to 3 years)
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Andrew Armstrong, MD, Duke University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Pro00115687
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.